Drug Resistance in Leishmaniasis

Clinical Microbiology Reviews - Tập 19 Số 1 - Trang 111-126 - 2006
Simon L. Croft1,2,3, Shyam Sundar1,2,3, Alan H. Fairlamb1,2,3
1Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, United Kingdom
2Division of Biological Chemistry and Molecular Biology, Wellcome Trust Biocentre, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom
3Infectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005 India

Tóm tắt

SUMMARY Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs has been used for over 60 years for leishmaniasis treatment, it is only in the past 2 years that the mechanisms of action and resistance have been identified, related to drug metabolism, thiol metabolism, and drug efflux. With the introduction of new therapies, including miltefosine in 2002 and paromomycin in 2005-2006, it is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.

Từ khóa


Tài liệu tham khảo

10.26719/2003.9.4.837

Aikat, B. K., S. Sahaya, A. G. Pathania, P. K. Bhattacharya, N. Desai, L. S. Prasad, S. Mishra, and S. Jain. 1979. Clinical profile of cases of kala-azar in Bihar. Indian J. Med. Res.70:563-570.

Al-Jaser M. H. 1995. Drug sensitivity of cutaneous leishmaniasis in Al-Kharj Saudi Arabia. Ph.D. thesis. University of London London England.

10.1023/A:1016251023427

Allen, S., and R. A. Neal. 1989. The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates, p. 711-720. In D. T. Hart (ed.), Leishmaniasis. Plenum Press, New York, N.Y.

10.1086/324161

10.1016/S0166-6851(01)00285-7

Asilian, A., T. Jalayer, M. Nilforooshzadeh, R. L. Ghassemi, R. Peto, S. Wayling, P. Olliaro, and F. Modabber. 2003. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull. W. H. O.81:353-359.

10.1128/AAC.22.3.380

10.1128/AAC.46.12.3731-3738.2002

10.1016/0166-6851(88)90166-1

10.1097/00002030-199910010-00015

10.4269/ajtmh.1981.30.566

Berman, J. D., R. Badaro, C. P. Thakur, K. M. Wasunna, K. Behbehani, R. Davidson, F. Kuzoe, L. Pang, K. Weerasuriya, and A. D. Bryceson. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. W. H. O.76:25-32.

10.4269/ajtmh.1982.31.459

10.1016/0006-2952(87)90689-7

10.4269/ajtmh.1983.32.753

10.1128/AAC.27.6.916

10.1126/science.287.5457.1479

10.4269/ajtmh.2004.70.72

10.1016/S1471-4922(03)00069-2

10.1128/AAC.47.10.3073-3079.2003

10.1046/j.1365-3156.2001.00795.x

10.1128/AAC.42.12.3245

Burguera, J. L., M. Burguera, Y. Petit de Pena, A. Lugo, and N. Anez. 1993. Selective determination of antimony(III) and antimony(V) in serum and urine and of total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimonate. J. Trace Elem. Med. Biol.10:66-70.

10.1016/S0021-9258(18)55077-8

10.1128/AAC.41.4.818

10.1016/0166-6851(94)00154-5

Carson, P. E. 1984. 8-aminoquinolines, p. 83-121. In W. Peters and W. H. G. Richards (ed.), Antimalarial drugs II. Springer-Verlag, Berlin, Germany.

10.1128/AAC.47.5.1529-1535.2003

10.1016/0035-9203(85)90200-7

10.1016/0035-9203(90)90263-E

10.1016/S0166-6851(03)00162-2

10.1086/381203

10.1016/0166-6851(90)90092-Z

Croft, S. L., and R. Brun. 2003. In vitro and in vivo models for the identification and evaluation of drugs active against Trypanosoma and Leishmania, p. 165-175. In A. H. Fairlamb, R. Ridley, and H. Vial (ed.), Drugs against parasitic diseases: R&D methodologies and issues. [Online.] World Health Organization, Geneva, Switzerland. http://www.who.int/tdr/publication/publications/prd-drug.htm .

10.1016/j.pt.2003.09.008

Croft S. L. and K. Seifert. 2005. Miltefosine: interactions with other anti-leishmanial drugs. Abstracts of the 3rd World Congress on Leishmaniosis 10-15 April 2005 Palermo Italy p. 57.

10.2174/1381612023396258

10.1016/S0140-6736(02)08160-6

10.1111/j.1432-1033.1995.tb20583.x

10.1016/S0169-4758(99)01609-9

10.1136/bmj.326.7385.377

10.1016/S0966-842X(97)01033-0

10.1016/S0966-842X(00)01873-4

10.1042/BJ20040283

10.1016/S0035-9203(01)90223-8

10.1179/000349803225002499

10.1016/0166-6851(94)90095-7

10.4269/ajtmh.2001.65.685

10.1093/jac/44.1.71

Docampo, R., and S. N. Moreno. 1986. Free radical metabolism of antiparasitic agents. Fed. Proc.45:2471-2476.

10.1128/AAC.42.8.2141

10.1093/jac/49.suppl_1.7

10.1016/0190-9622(92)70175-F

10.1016/0035-9203(87)90011-3

10.1128/AAC.43.2.278

10.1128/AAC.41.5.1064

10.1016/0014-4894(66)90082-8

10.1016/S0001-706X(01)00197-8

10.1128/AAC.45.6.1872-1875.2001

10.1128/AAC.41.4.827

10.1023/A:1022823605068

10.4269/ajtmh.1994.51.758

10.1128/AAC.45.3.913-916.2001

Fries, D. S., and A. H. Fairlamb. 2003. Antiprotozoal agents, p. 1033-1087. In J. Abraham (ed.), Burger's medicinal chemistry and drug discovery: chemotherapeutic agents. John Wiley & Sons, New York, N.Y.

Garnier, T., and S. L. Croft. 2002. Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs3:538-544.

10.1128/CMR.12.4.501

10.1073/pnas.85.20.7602

10.1042/bj0370198

10.1074/jbc.M403959200

10.1016/S0166-6851(03)00142-7

10.3201/eid0912.030178

10.1080/00034983.1992.11812717

10.1016/0014-4894(89)90173-2

10.1093/emboj/16.11.3057

Guerin, P. J., P. Olliaro, S. Sundar, M. Boelaert, S. L. Croft, P. Desjeux, M. K. Wasunna, and A. D. Bryceson. 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis.ii:494-501.

10.1046/j.1365-2958.1999.01634.x

10.1042/bj2720281

10.1007/BF00933004

Jha, S. N., N. K. Singh, and T. K. Jha. 1991. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J. Assoc. Physicians India39:314-316.

10.1016/0035-9203(83)90058-5

Jha, T. K., N. K. Singh, and S. N. Jha. 1992. Therapeutic use of sodium stibogluconate in kala-azar from some hyperendemic districts of N. Bihar, India. (Abstract) J. Assoc. Physicians India40:868.

Am. J. Trop. Med. Hyg.

10.1146/annurev.biochem.73.011303.073706

10.1111/j.1574-6968.1994.tb07140.x

10.4269/ajtmh.1978.27.751

10.1016/S0304-4017(01)00399-5

10.1097/00002030-199906180-00009

10.1093/jac/dkg356

10.1074/jbc.M102351200

10.1126/science.283.5403.806

10.1093/genetics/154.3.985

10.1016/S0020-7519(02)00091-7

10.1016/S0190-9622(98)70483-9

10.1086/314896

10.1042/bj2880977

10.1179/000349803225002615

10.1080/00034983.1994.11812832

10.1051/parasite/1998052167

10.1006/excr.1997.3500

10.1007/BF00931504

Marr, J. J. 1991. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J. Lab. Clin. Med.118:111-119.

10.1128/AAC.42.2.352

10.1086/515085

10.1179/000349803225002516

10.1073/pnas.93.19.10383

10.1128/AAC.37.7.1504

10.1172/JCI114009

10.1093/infdis/165.3.528

10.1093/jac/35.5.577

10.1093/jac/14.5.463

10.1016/S0021-9258(19)86518-3

10.1016/0923-2508(91)90089-S

10.1002/j.1460-2075.1991.tb08035.x

10.1006/bbrc.1996.1098

10.1128/AAC.47.8.2397-2403.2003

10.1074/jbc.M308352200

10.2174/1389450023347588

Peters, W. 1981. The treatment of kala-azar-new approaches to an old problem. Indian J. Med. Res.73(Suppl.):1-18.

10.1128/AAC.48.7.2409-2414.2004

10.1128/AAC.40.12.2785

10.1111/j.1365-3156.2004.01251.x

10.1016/S0035-9203(03)90167-2

10.1016/S0166-6851(02)00280-3

10.1128/AAC.37.9.1842

10.1016/j.bbrc.2003.09.227

10.1016/S0924-8579(03)00125-0

10.1128/AAC.42.12.3097

10.1128/AAC.45.7.2064-2069.2001

10.1128/AAC.41.5.972

10.1074/jbc.M005423200

10.1038/clpt.1991.61

10.1006/expr.2001.4663

10.1016/1043-6618(89)90192-8

10.1086/377133

10.1086/383321

10.4269/ajtmh.2002.66.147

10.1074/jbc.M301975200

10.1046/j.1432-1327.2000.01605.x

10.1046/j.1365-3156.2001.00778.x

10.1056/NEJMoa021556

10.1086/377542

10.1086/318121

Sundar, S., and H. W. Murray. 2005. Availability of miltefosine for the treatment of kala-azar in India. Bull. W. H. O.83:394-395.

10.4269/ajtmh.2001.65.193

10.1136/bmj.308.6924.307

10.1016/0035-9203(94)90106-6

10.1016/S0035-9203(01)90160-9

10.1016/S0035-9203(00)90131-7

10.1136/bmj.296.6636.1557

Thakur, C. P., M. Kumar, and A. K. Pandey. 1991. Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate. Indian J. Med. Res.93:103-110.

10.1136/bmj.288.6421.895

Thakur, C. P., G. P. Sinha, A. K. Pandey, N. Kumar, P. Kumar, S. M. Hassan, S. Narain, and R. K. Roy. 1998. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann. Trop. Med. Parasitol.92:561-569.

10.1016/0006-2952(85)90122-4

10.1046/j.1365-3156.2000.00555.x

10.1074/jbc.M311039200

10.1016/S0140-6736(00)04232-X

Wasunna M. K. J. R. RAashid J. Mbui G. Kirigi D. Kinoti H. Lodenyo J. M. Felton A. J. Sabin and J. Horton. 2005. A phase II dose-rising study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg. 73 : 871-876.

White, N. J., and W. Pongtavornpinyo. 2002. The de novo selection of drug-resistant malaria parasites. Proc. R. Soc. Lond. B270:545-554.

10.1074/jbc.M405635200

10.1007/s00775-003-0468-1

Yan, S. C., I. L. K. Wang, L. M. C. Chow, and H. Z. Sun. 2003. Rapid reduction of pentavalent antimony by trypanothione: potential relevance to antimonial activation. Chem. Commun.2:266-287.

Yardley V. S. L. Croft S. De Donker J. C. Dujardin K. Siddhartha C. Miranda A. Llanos-Cuentas and F. Chappuis. 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am. J. Trop. Med. Hyg. 73 : 272-275.

Yeates, C. 2002. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr. Opin. Investig. Drugs3:1446-1452.

10.1128/AAC.47.9.2717-2724.2003

10.1074/jbc.M404383200

Thông tin
Thông tin xuất bản

Clinical Microbiology Reviews

Tập 19 Số 1

111-126

Thông tin tác giả